Renalytix Plc
RENXF
$0.091
-$0.039-30.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.73% | 13.13% | -26.10% | -40.52% | -52.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.73% | 13.13% | -26.10% | -40.52% | -52.63% |
| Cost of Revenue | -15.94% | -18.28% | -0.33% | -32.49% | -27.87% |
| Gross Profit | 332.56% | 123.23% | -154.55% | -52.39% | -115.75% |
| SG&A Expenses | -46.00% | -29.13% | -45.68% | -21.39% | -26.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.64% | -41.53% | -42.69% | -16.62% | -26.41% |
| Operating Income | 53.97% | 44.38% | 43.79% | 13.67% | 24.25% |
| Income Before Tax | 53.46% | 36.27% | 36.05% | 18.80% | 15.06% |
| Income Tax Expenses | -- | -100.00% | -- | -- | -- |
| Earnings from Continuing Operations | 53.44% | 36.29% | 36.04% | 18.76% | 15.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.44% | 36.29% | 36.04% | 18.76% | 15.05% |
| EBIT | 53.97% | 44.38% | 43.79% | 13.67% | 24.25% |
| EBITDA | 53.98% | 44.94% | 43.76% | 13.28% | 24.75% |
| EPS Basic | 58.26% | 56.79% | 43.96% | 37.49% | 32.98% |
| Normalized Basic EPS | 57.58% | 61.89% | 51.86% | 34.12% | 32.16% |
| EPS Diluted | 59.36% | 56.79% | 43.46% | 35.71% | 31.16% |
| Normalized Diluted EPS | 57.58% | 61.89% | 51.86% | 34.12% | 32.16% |
| Average Basic Shares Outstanding | 11.53% | 47.39% | 14.14% | 29.88% | 26.69% |
| Average Diluted Shares Outstanding | 11.53% | 47.39% | 14.14% | 29.88% | 26.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
